

Anna Caroli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4373484/publications.pdf>

Version: 2024-02-01

62
papers

4,014
citations

101384

36
h-index

118652

62
g-index

66
all docs

66
docs citations

66
times ranked

5627
citing authors

#	ARTICLE	IF	CITATIONS
1	Consensus-Based Technical Recommendations for Clinical Translation of Renal Phase Contrast MRI. Journal of Magnetic Resonance Imaging, 2022, 55, 323-335.	1.9	22
2	The use of AVF.SIM system for the surgical planning of arteriovenous fistulae in routine clinical practice. Journal of Vascular Access, 2022, , 112972982110626.	0.5	1
3	Diffusion-Weighted Magnetic Resonance Imaging: Clinical Potential and Applications. Journal of Clinical Medicine, 2022, 11, 3339.	1.0	3
4	Chest X-ray for predicting mortality and the need for ventilatory support in COVID-19 patients presenting to the emergency department. European Radiology, 2021, 31, 1999-2012.	2.3	86
5	Cerebral superb microvascular imaging in preterm neonates: in vivo evaluation of thalamic, striatal, and extra-striatal angioarchitecture. Neuroradiology, 2021, 63, 1103-1112.	1.1	12
6	Post-discharge chest CT findings and pulmonary function tests in severe COVID-19 patients. European Journal of Radiology, 2021, 138, 109676.	1.2	39
7	Basic principles and new advances in kidney imaging. Kidney International, 2021, 100, 1001-1011.	2.6	25
8	Renal Diffusion-Weighted Imaging (DWI) for Apparent Diffusion Coefficient (ADC), Intravoxel Incoherent Motion (IVIM), and Diffusion Tensor Imaging (DTI): Basic Concepts. Methods in Molecular Biology, 2021, 2216, 187-204.	0.4	5
9	Incorporating radiomics into clinical trials: expert consensus endorsed by the European Society of Radiology on considerations for data-driven compared to biologically driven quantitative biomarkers. European Radiology, 2021, 31, 6001-6012.	2.3	53
10	Phase-contrast magnetic resonance imaging to assess renal perfusion: a systematic review and statement paper. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2020, 33, 3-21.	1.1	26
11	Does MRI trump pathology? A new era for staging and monitoring of kidney fibrosis. Kidney International, 2020, 97, 442-444.	2.6	11
12	Technical recommendations for clinical translation of renal MRI: a consensus project of the Cooperation in Science and Technology Action PARENCHIMA. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2020, 33, 131-140.	1.1	44
13	Consensus-based technical recommendations for clinical translation of renal diffusion-weighted MRI. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2020, 33, 177-195.	1.1	61
14	Functional Magnetic Resonance Imaging Versus Kidney Biopsy to Assess Response to Therapy in Nephrotic Syndrome: A Case Report. Kidney Medicine, 2020, 2, 804-809.	1.0	2
15	Prognostic value of Alzheimer's biomarkers in mild cognitive impairment: the effect of age at onset. Journal of Neurology, 2019, 266, 2535-2545.	1.8	11
16	Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial. PLoS Medicine, 2019, 16, e1002777.	3.9	42
17	Imaging of Kidney Cysts and Cystic Kidney Diseases in Children: An International Working Group Consensus Statement. Radiology, 2019, 290, 769-782.	3.6	69
18	Magnetic resonance imaging biomarkers for chronic kidney disease: a position paper from the European Cooperation in Science and Technology Action PARENCHIMA. Nephrology Dialysis Transplantation, 2018, 33, ii4-ii14.	0.4	91

#	ARTICLE	IF	CITATIONS
19	Diffusion-weighted magnetic resonance imaging to assess diffuse renal pathology: a systematic review and statement paper. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, ii29-ii40.	0.4	111
20	Functional magnetic resonance imaging of the kidneys: where do we stand? The perspective of the European COST Action PARENCHIMA. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, ii1-ii3.	0.4	32
21	Magnetic resonance imaging T1- and T2-mapping to assess renal structure and function: a systematic review and statement paper. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, ii41-ii50.	0.4	75
22	Renal blood oxygenation level-dependent magnetic resonance imaging to measure renal tissue oxygenation: a statement paper and systematic review. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, ii22-ii28.	0.4	88
23	Automatic Segmentation of Kidneys using Deep Learning for Total Kidney Volume Quantification in Autosomal Dominant Polycystic Kidney Disease. <i>Scientific Reports</i> , 2017, 7, 2049.	1.6	115
24	Kidney volume measurement methods for clinical studies on autosomal dominant polycystic kidney disease. <i>PLoS ONE</i> , 2017, 12, e0178488.	1.1	40
25	Cortical sources of resting state EEG rhythms are related to brain hypometabolism in subjects with Alzheimer's disease: an EEG-PET study. <i>Neurobiology of Aging</i> , 2016, 48, 122-134.	1.5	53
26	Effect of Sirolimus on Disease Progression in Patients with Autosomal Dominant Polycystic Kidney Disease and CKD Stages 3b-4. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 785-794.	2.2	35
27	Prediction of AD dementia by biomarkers following the NIA-AA and A&W diagnostic criteria in MCI patients from three European memory clinics. <i>Alzheimer's and Dementia</i> , 2015, 11, 1191-1201.	0.4	71
28	Striatum and entorhinal cortex atrophy in AD mouse models: MRI comprehensive analysis. <i>Neurobiology of Aging</i> , 2015, 36, 776-788.	1.5	25
29	Mild cognitive impairment with suspected nonamyloid pathology (SNAP). <i>Neurology</i> , 2015, 84, 508-515.	1.5	122
30	Alzheimer Disease Biomarkers as Outcome Measures for Clinical Trials in MCI. <i>Alzheimer Disease and Associated Disorders</i> , 2015, 29, 101-109.	0.6	14
31	Validation of an optimized SPM procedure for FDG-PET in dementia diagnosis in a clinical setting. <i>NeuroImage: Clinical</i> , 2014, 6, 445-454.	1.4	172
32	A Standardized [18F]-FDG-PET Template for Spatial Normalization in Statistical Parametric Mapping of Dementia. <i>Neuroinformatics</i> , 2014, 12, 575-593.	1.5	240
33	O2-13-03: MILD COGNITIVE IMPAIRMENT WITH SUSPECTED NON AD PATHOLOGY (SNAP): PREDICTION OF PROGRESSION TO DEMENTIA. , 2014, 10, P194-P195.		0
34	Computer-aided diagnostic reporting of FDG PET for the diagnosis of Alzheimer's disease. <i>Clinical and Translational Imaging</i> , 2013, 1, 279-288.	1.1	3
35	Young Women With Polycystic Liver Disease Respond Best to Somatostatin Analogues: A Pooled Analysis of Individual Patient Data. <i>Gastroenterology</i> , 2013, 145, 357-365.e2.	0.6	76
36	Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial. <i>Lancet</i> , The, 2013, 382, 1485-1495.	6.3	218

#	ARTICLE	IF	CITATIONS
37	Diagnostic accuracy of markers for prodromal Alzheimer's disease in independent clinical series. <i>Alzheimer's and Dementia</i> , 2013, 9, 677-686.	0.4	51
38	Metabolic Networks Underlying Cognitive Reserve in Prodromal Alzheimer Disease: A European Alzheimer Disease Consortium Project. <i>Journal of Nuclear Medicine</i> , 2013, 54, 894-902.	2.8	108
39	Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease. <i>Neurology</i> , 2013, 80, 1048-1056.	1.5	161
40	Validation of a patient-specific hemodynamic computational model for surgical planning of vascular access in hemodialysis patients. <i>Kidney International</i> , 2013, 84, 1237-1245.	2.6	67
41	Summary Metrics to Assess Alzheimer Disease-Related Hypometabolic Pattern with ¹⁸ F-FDG PET: Head-to-Head Comparison. <i>Journal of Nuclear Medicine</i> , 2012, 53, 592-600.	2.8	79
42	Resting metabolic connectivity in prodromal Alzheimer's disease. A European Alzheimer Disease Consortium (EADC) project. <i>Neurobiology of Aging</i> , 2012, 33, 2533-2550.	1.5	108
43	Intermediate Volume on Computed Tomography Imaging Defines a Fibrotic Compartment that Predicts Glomerular Filtration Rate Decline in Autosomal Dominant Polycystic Kidney Disease Patients. <i>American Journal of Pathology</i> , 2011, 179, 619-627.	1.9	19
44	Clinical Study Protocol for the ARCH Project Computational Modeling for Improvement of Outcome after Vascular Access Creation. <i>Journal of Vascular Access</i> , 2011, 12, 369-376.	0.5	23
45	Disease Tracking Markers for Alzheimer's Disease at the Prodromal (MCI) Stage. <i>Journal of Alzheimer's Disease</i> , 2011, 26, 159-199.	1.2	120
46	Mapping brain morphological and functional conversion patterns in amnesic MCI: a voxel-based MRI and FDG-PET study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 36-45.	3.3	95
47	The new Alzheimer's criteria in a naturalistic series of patients with mild cognitive impairment. <i>Journal of Neurology</i> , 2010, 257, 2004-2014.	1.8	44
48	Metabolic Compensation and Depression in Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2010, 29, 37-45.	0.7	18
49	Reducing Polycystic Liver Volume in ADPKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 783-789.	2.2	126
50	Sirolimus Therapy to Halt the Progression of ADPKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2010, 21, 1031-1040.	3.0	157
51	Clinical and medial temporal features in a family with mood disorders. <i>Neuroscience Letters</i> , 2010, 468, 93-97.	1.0	23
52	Functional compensation in incipient Alzheimer's disease. <i>Neurobiology of Aging</i> , 2010, 31, 387-397.	1.5	28
53	The dynamics of Alzheimer's disease biomarkers in the Alzheimer's Disease Neuroimaging Initiative cohort. <i>Neurobiology of Aging</i> , 2010, 31, 1263-1274.	1.5	126
54	In vivo mapping of amyloid toxicity in Alzheimer disease. <i>Neurology</i> , 2009, 72, 1504-1511.	1.5	87

#	ARTICLE	IF	CITATIONS
55	Quantitative evaluation of Alzheimer's disease. Expert Review of Medical Devices, 2009, 6, 569-588.	1.4	14
56	Relating one-year cognitive change in mild cognitive impairment to baseline MRI features. NeuroImage, 2009, 47, 1363-1370.	2.1	90
57	SPECT Predictors of Cognitive Decline and Alzheimer's Disease in Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2009, 17, 761-772.	1.2	42
58	Brain SPECT in subtypes of mild cognitive impairment. Journal of Neurology, 2008, 255, 1344-1353.	1.8	54
59	MRI-Based Automated Computer Classification of Probable AD Versus Normal Controls. IEEE Transactions on Medical Imaging, 2008, 27, 509-520.	5.4	133
60	Brain perfusion correlates of medial temporal lobe atrophy and white matter hyperintensities in mild cognitive impairment. Journal of Neurology, 2007, 254, 1000-1008.	1.8	36
61	Cerebral perfusion correlates of conversion to Alzheimer's disease in amnesic mild cognitive impairment. Journal of Neurology, 2007, 254, 1698-1707.	1.8	81
62	Structural brain imaging in patients with cognitive impairment in the year 2015. Future Neurology, 2006, 1, 77-86.	0.9	2